2026-01-01 - Analysis Report
Okay, let's break down the analysis of Eli Lilly and Co. (LLY) based on the provided data.

**Company Overview:** Eli Lilly and Co. is a major pharmaceutical company focused on developing and marketing medicines across a range of therapeutic areas.

**1) Return Rate Comparison:**

*   **LLY Cumulative Return:** 308.74%
*   **VOO (S&P 500) Cumulative Return:** 102.21%
*   **Divergence:** 206.5
*   **Relative Divergence:** 85.1

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO). The divergence of 206.5 indicates a substantial difference in returns. The relative divergence of 85.1 suggests that the current divergence is high compared to its historical range, indicating a strong period of outperformance.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2024-2026  | 310.0% | 83.5% | 204.0% | 0.0  | 967.5  |

*   **CAGR (Compound Annual Growth Rate):** 310% - Extremely high growth rate.
*   **MDD (Maximum Drawdown):** 83.5% - Indicates significant potential downside risk (large peak-to-trough decline).
*   **Alpha:** 204% -  A measure of how much better the investment performed compared to the market benchmark (risk-adjusted). Very high alpha suggests strong outperformance.
*   **Beta:** 0.0 -  Indicates that the stock has virtually no correlation with the overall market. This could mean that LLY's performance is driven by company-specific factors (e.g., drug development pipeline, regulatory approvals) rather than broader market trends.
*   **Cap(B):** 967.5 - Market capitalization is very large.

**Analysis:** The high CAGR and Alpha highlight strong performance, but the high MDD indicates significant risk. The Beta of 0.0 suggests that LLY's performance is largely independent of the overall market, making it a potentially good diversifier.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 1079.75
*   **Last Market Price:** 1079.07 (change: -0.06)
*   **5-day SMA:** 1076.97
*   **20-day SMA:** 1042.203
*   **60-day SMA:** 960.5238

**Analysis:** The stock price is trading above all three moving averages (5-day, 20-day, and 60-day), which is generally considered a bullish signal. The fact that the 5-day SMA is slightly above the 20-day SMA, which is above the 60-day SMA, confirms the upward trend.  The very small change from the previous close indicates relative price stability in the very short term.

**3) Indicator Analysis:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 82.95 (Overbought)
*   **PPO:** -0.0633
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Relative Divergence Change:** 0.2 (+) (Short-term increase)
*   **Expected Return:** 48.6% (Over 2 years, compared to S&P 500)

**Analysis:** The MRI suggests a high investment recommendation. However, the RSI is in overbought territory (above 70), suggesting that the stock may be due for a pullback or correction. The negative PPO indicates the stock price is below its moving average, which could suggest the price is in a short-term downtrend, though this contradicts the SMA analysis in section 2. The recent increase in relative divergence and high expected return further reinforce the positive outlook. But the overbought RSI means that the stock price is likely to decline in the near term.

**4) Recent News & Significant Events:**

*   **Weight-loss pill pricing and insider filings:** Suggests ongoing focus and potential impact from Eli Lilly's obesity drug.
*   **Stock split candidate:** Indicates strong performance and potential for increased accessibility to investors.
*   **Shares Sold by Farmers & Merchants Investments Inc.:** This could indicate profit-taking or a portfolio rebalancing by the institution.
*   **Bernstein reaffirms price target:** Shows continued confidence from analysts.
*   **Where Will Eli Lilly Be in 10 Years?:** A long-term outlook piece, likely addressing growth prospects and challenges.

**Analysis:** The news headlines are generally positive, focusing on the company's weight-loss drug, potential stock split, and analyst confidence. The "shares sold" headline could be a minor concern, but should be considered in the context of the overall positive sentiment.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 1093.22 / 1500.00 / 770.00
*   **Recent Rating Changes:** No specific changes provided.

**Analysis:** Strong "Buy" consensus from a large number of analysts suggests positive sentiment. The average target price (1093.22) is slightly above the current price, indicating potential upside. The high target price (1500.00) represents a very optimistic scenario, while the low target price (770.00) suggests potential downside risk.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3  | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

**Analysis:** The provided earnings data shows a clear upward trend in both EPS (Earnings Per Share) and revenue. The increase in EPS from 1.08 (2024-10-30) to 6.22 (2025-10-30) is remarkable. The consistent growth in revenue further supports the positive earnings trend.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $17.60B   | 82.91%       |
| 2025-06-30 | $15.56B   | 84.27%       |
| 2025-03-31 | $12.73B   | 82.53%       |
| 2024-12-31 | $13.53B   | 82.24%       |
| 2024-09-30 | $11.44B   | 81.02%       |

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-09-30 | $23.79B   | 23.46% |
| 2025-06-30 | $18.27B   | 30.98% |
| 2025-03-31 | $15.76B   | 17.50% |
| 2024-12-31 | $14.19B   | 31.07% |
| 2024-09-30 | $14.24B   | 6.81%  |

**Analysis:** The financials paint a very strong picture. Revenue is growing consistently, and profit margins are extremely high (above 80%).  Equity is increasing, and ROE (Return on Equity) is generally high, indicating efficient use of shareholder investment.  There's some volatility in ROE, but the recent numbers are quite healthy.

**7) Comprehensive Analysis (Summary):**

*   **Positive Outlook:** Eli Lilly (LLY) has significantly outperformed the S&P 500 and exhibits strong growth, as evidenced by its high CAGR, Alpha, EPS, revenue, and profit margins. Analyst sentiment is overwhelmingly positive.
*   **Company-Specific Drivers:** The low Beta suggests that LLY's performance is largely driven by its own innovations (e.g., drug pipeline, approvals) rather than market trends. The success of its weight-loss drug is likely a major factor.
*   **Risk Factors:** The high MDD highlights the potential for significant price declines. The RSI is in overbought territory, suggesting a possible near-term correction. The stock price is likely to decline in the near term due to recent short-term price changes.
*   **Investment Recommendation:** Based on the provided data, LLY appears to be a strong investment for the long term. The Market Risk Indicator supports a "High Investment Recommended" approach. However, given the overbought RSI, it might be prudent to wait for a pullback or correction before initiating or adding to a position. Investors should also be mindful of the high MDD and be prepared for potential volatility. Furthermore, profit taking based on Farmers and Merchants is concerning in the short term.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.